Firmenprofil zu VIRTUS LIFESCI BIOTECH PRODUCTS ETF ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
The Virtus Biotech ETF seeks to replicate the overall financial performance, encompassing both price appreciation and income generation, of the LifeSci Biotechnology Products Index, prior to any deductions for fees and expenses. This index specifically comprises biotechnology companies that have received approval from the FDA for at least one drug therapy. Furthermore, the fund underwent a name change on February 27, transitioning from Virtus LifeSci Biotech Products ETF to its current designation.
